Health Care & Life Sciences » Biotechnology | ProMIS Neurosciences Inc.

ProMIS Neurosciences Inc. | Balance Sheet

Fiscal year is January-December. All values CAD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
36.30
25.00
944.20
753.20
1,731.20
2,431.30
Total Accounts Receivable
116.10
129.20
74.20
46.30
46.10
54.70
Other Current Assets
57.70
51.80
55.40
98.10
330.00
423.20
Total Current Assets
210.00
206.00
1,073.90
897.60
2,107.30
2,909.20
Net Property, Plant & Equipment
18.40
6.90
1.90
1.90
1.90
1.90
Intangible Assets
93.30
81.70
75.00
68.30
61.60
55
Total Assets
321.80
294.50
1,150.70
967.80
2,170.80
2,966
ST Debt & Current Portion LT Debt
-
-
118.30
120.90
-
Accounts Payable
538.10
421.60
415.40
760.50
260.90
Other Current Liabilities
-
71.20
17.00
17.00
376.50
Total Current Liabilities
538.10
492.80
550.80
898.40
637.50
Total Liabilities
538.10
492.80
550.80
898.40
637.50
Common Equity (Total)
216.20
198.20
600.00
69.40
1,533.40
Total Shareholders' Equity
216.20
198.20
600.00
69.40
1,533.40
Total Equity
216.20
198.20
600.00
69.40
1,533.40
Liabilities & Shareholders' Equity
321.80
294.50
1,150.70
967.80
2,170.80

About ProMIS Neurosciences

View Profile
Address
1920 Yonge Street
Toronto Ontario M4S 3E2
Canada
Employees -
Website http://www.promisneurosciences.com
Updated 07/08/2019
ProMIS Neurosciences, Inc. operates as a development stage biotech company. It discovers and develops precision therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative diseases, in particular Alzheimer's disease and amyotrophic lateral sclerosis. The company was founded by Neil Cashman and Vigen Nazarian on January 23, 2004 and is headquartered in Toronto, Canada.